Direct Comparison of $[^{18}\text{F}]$F-DPA with $[^{18}\text{F}]$DPA-714 and $[^{11}\text{C}]$PBR28 for Neuroinflammation Imaging in the same Alzheimer’s Disease Model Mice and Healthy Controls

Francisco R. López-Picón1,2, Thomas Keller3, Diana Bocancea1,2, Jatta S. Helin1,2, Anna Krzyczmonik3, Semi Helin3, Annelaure Damont4, Frédéric Dollé4, Juha O. Rinne5,6, Merja Haaparanta-Solin1,2, and Olof Solin3,7,8

1PET Preclinical Imaging Laboratory, Turku PET Centre, University of Turku, Turku, Finland
2MediCity Research Laboratory, University of Turku, Turku, Finland
3Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
4CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France
5Turku PET Centre, University of Turku, Turku, Finland
6Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland
7Department of Chemistry, University of Turku, Turku, Finland
8Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, Finland

2021

Abstract
Purpose: In this study we compared the recently developed TSPO tracer $[^{18}\text{F}]$F-DPA, with $[^{18}\text{F}]$DPA-714 and $[^{11}\text{C}]$PBR28 by performing in vivo PET imaging on the same Alzheimer’s disease mouse model APP/PS1-21 (TG) and wild-type (WT) mice with all three radiotracers.

Procedures: To compare the radiotracer uptake, percentage of injected dose/mL (%ID/mL), standardized uptake value ratios to cerebellum (SUVR$_{\text{CB}}$), and voxel-wise analyses were performed.

Results: The peak uptake of $[^{18}\text{F}]$F-DPA was higher than 4.3% ID/mL, while $[^{18}\text{F}]$DPA-714 reached just over 3% ID/mL, and $[^{11}\text{C}]$PBR28 was over 4% ID/mL in only one brain region in the WT mice. The peak/60-min uptake ratios of $[^{18}\text{F}]$F-DPA were significantly higher ($p < 0.001$) than those of $[^{18}\text{F}]$DPA-714 and $[^{11}\text{C}]$PBR28. The differences in $[^{18}\text{F}]$F-DPA SUVR$_{\text{CB}}$ between WT and TG mice were highly significant ($p < 0.001$) in the three studied time periods after injection. $[^{18}\text{F}]$DPA-714 uptake was significantly higher in TG mice starting in the 20–40-min timeframe and increased thereafter, whereas $[^{11}\text{C}]$PBR28 uptake became significant at 10–20 min ($p < 0.05$). The voxel-wise analysis confirmed the differences between the radiotracers.

Conclusions: $[^{18}\text{F}]$F-DPA displays higher brain uptake, higher TG-to-WT SUVR$_{\text{CB}}$ ratios, and faster clearance than $[^{18}\text{F}]$DPA-714 and $[^{11}\text{C}]$PBR28, and could prove useful for detecting low levels of inflammation and allow for shorter dynamic PET scans.

Keywords Alzheimer’s disease · Neuroinflammation · $[^{18}\text{F}]$F-DPA · $[^{18}\text{F}]$DPA-714 · $[^{11}\text{C}]$PBR28 · TSPO · PET · Microglia

Correspondence to: Francisco R. López-Picón; e-mail: francisco.lopez@utu.fi
Introduction

Neuroinflammation is associated with several neurological diseases, such as multiple sclerosis (MS), Alzheimer’s disease (AD), and stroke. Innate pathology triggers inflammation that induces an increase in the expression of mitochondrial 18-kDa translocator protein (TSPO) in the microglia. TSPO is the main target for the PET tracers currently used for imaging neuroinflammation in vivo [1–5].

Although [11C]PK11195, one of the first TSPO PET tracers, is still routinely used in clinical imaging, it has several limitations, including poor signal-to-noise ratio, high lipophilicity, low blood–brain barrier penetration, and the short half-life of carbon-11 [6, 7]. Consequently, numerous second-generation PET tracers have been developed, including [11C]PBR28, [18F]GE180, [18F]DPA-714, and [18F]F-DPA, to name a few [8–12].

The half-life of fluorine-18 (t1/2 = 109.8 min) makes it a more desirable radioisotope than carbon-11 (t1/2 = 20.3 min) for the development of radiotracers because of the possibility of distribution to PET centers lacking an on-site cyclotron. Furthermore, fluorine-18 emits positrons with low energy (E_{β+ max} = 0.63 MeV). Consequently, the positrons have a short range in tissue and provide higher-resolution PET images than those afforded by carbon-11 radiotracers. For these reasons, several 18F-labeled tracers have been developed, notably among them [18F]DPA-714, which presents good binding potential and bioavailability. According to several animal studies, [18F]DPA-714 is better for PET imaging than [11C]PK11195, due to its low nonspecific binding in the brain and the longer half-life of the labeling radionuclide [13, 14]. Recent longitudinal studies using mouse and rat models of AD have shown an increase in [18F]DPA-714 uptake with disease progression [15–17]; however, the results of human [18F]DPA-714 PET studies in AD patients have been contradictory [18–20].

We have previously published the synthesis of [18F]F-DPA, an analogue of [18F]DPA-714, by an electrophilic 18F-labeling route and showed that the position of the label directly on the aromatic moiety imparts a higher in vivo stability than that of [18F]DPA-714 in Sprague–Dawley rats [12]. More recent studies have demonstrated the specificity of [18F]F-DPA towards TSPO and its usefulness in imaging glial activation in the APP-Ps1/21 mouse model of AD [11] and in a model of ischemic stroke [21]. In addition, a study comparing electrophilic and nucleophilic syntheses of [18F]F-DPA demonstrated that a 100-fold difference in injected mass of [18F]F-DPA affected both the tracer kinetics and uptake in the APP-Ps1/21 mouse model. The higher injected mass gave a faster washout and more rapid establishment of tracer equilibrium while still providing a significant uptake difference between age-matched TG and WT animals [10].

In this study we chose to compare [18F]F-DPA synthesized by the electrophilic approach with the clinically used TSPO tracers [18F]DPA-714 and [11C]PBR28 in the same TG and WT mice. The relative ease of the electrophilic synthetic procedure in our hands, the favorable kinetics of the tracer, and the high abundance of the target in TG mice motivated this study.

Materials and Methods

Tracer Synthesis

[18F]F-DPA and [18F]DPA-714 were synthesized according to the previously described procedures [19]. Two syntheses of [18F]F-DPA and [18F]DPA-714 were used for this study, and the final products were obtained with molar activities of 7.5 and 7.2 GBq/µmol for [18F]F-DPA and greater than 1 TBq/µmol for [18F]DPA-714. Six different [11C]PBR28 syntheses were produced with a mean molar activity of 570 GBq/µmol. All molar activities are decay-corrected to the start of radio-synthesis. [11C]PBR28 production was adapted from a published method [22], with some modifications. The detailed description of [11C]PBR28 production is included in the Supplementary information.

Animals

Six female transgenic APP-PS1/21 (TG) mice (9 months old; 27 ± 2 g) and 6 female WT (9 months old; 34 ± 6 g) littermates were used for this study. APP/PS1-21 mice (C57BL/6 J–TgN(Thy1–APPKM670/671NL; Thy1–PS1L166P) [23] were originally provided by Koesler (Rottenburg, Germany). All animals were group-housed under standard conditions (temperature 21 ± 2.0°C, humidity 55 ± 5%, with a 12-h light/dark cycle and ad libitum soy-free chow (RM3 [E] soya-free, 801,710, Special Diets Service, UK) and tap water. All animal experiments were approved by the Regional State Administrative Agency for Southern Finland (ESAVI/4499/04.10.07/2016 and ESAVI/3899/0404.10.07/2013), and the animal care complied with the guidelines of the International Council of Laboratory Animal Science (ICLAS). The study was performed in strict compliance with the ARRIVE guidelines and met the principles of the 3Rs (Replacement, Reduction, and Refinement) by using PET imaging to examine the same animals repeatedly.

In vivo Binding of [18F]F-DPA, [18F]DPA-714, and [11C]PBR28

The same 9-month-old WT (n = 6) and TG (n = 6) mice were imaged using [11C]PBR28 [18F]DPA-714 and [18F]F-DPA within a period of 10 days. The mice, anesthetized with a 2.5% isoflurane/oxygen mixture 30 min prior to tracer injection, were injected via a tail vein with [18F]F-DPA (injected dose 6.9 ± 0.2 MBq; 43 ± 18 µg/kg), [18F]DPA-714 (injected dose 6.8 ± 0.3 MBq; 0.8 ± 0.3 µg/kg), or [11C]PBR28 (injected dose 10.3 ± 0.8 MBq; 0.4 ± 0.1 µg/kg) for 60-min dynamic scanning using an Inveon multimodality scanner.
PET/computed tomography (CT) scanner (Siemens Medical Solutions, Knoxville, TN, USA). A few drops of Oftagel (2.5 mg/g; Santen, Tampere, Finland) were applied to the eyes of the animals to prevent eye dryness. The scanner has an axial 12.7-cm field of view and 10-cm transaxial field of view, generating images from 159 transaxial slices of voxel size of 0.78 × 0.78 × 0.8 mm³. CT preceded the PET modality for attenuation correction and anatomical reference. One of the TG animals imaged with [18F]F-DPA died during the scan, and hence this animal was excluded from the analysis.

**Analysis of PET Data**

The PET/CT images were pre-processed in MATLAB R2017a (The MathWorks, Natick, Massachusetts, USA) with an in-house semi-automated pipeline for preclinical images that use SPM12 (Wellcome Department of Cognitive Neurology, London, UK) pre-processing functionalities and analysis routines. Images were first cropped to a bounding box containing the heads, and individual PET images were co-registered through a rigid-body transformation to their corresponding CT scan. Subjects were spatially normalized through a two-step registration (a rigid followed by an affine transformation) of each subject’s CT to a template CT that was previously constructed as an average of several subjects and was aligned with an atlas T2-weighted MRI template [24]. The combination of transformations was then applied to the PET images, which were also re-sampled to a voxel size of 0.2 × 0.2 × 0.2 mm (trilinear interpolation), matching the anatomical atlas dimensions.

Volume of interest (VOI) analysis of whole brain, cortex, hippocampus (HIPPO), striatum (STR), thalamus (THA), and cerebellum (CB) was performed on each subject by averaging the signal inside a slightly modified version of the Ma et al. [24] atlas-delineated VOIs. Data were obtained as the percentage of injected dose/mL (%ID/mL) or standardized uptake value ratios to cerebellum (SUVRCB).

Prior to the voxel-wise analysis, single static frames representing three time periods after tracer injection (10–20 min, 20–40 min, and 40–60 min) were constructed by averaging the corresponding frames of the dynamic scans for each subject and each tracer. The resulting static images were intensity-normalized to the CB as a reference region (tissue-to-reference ratio images) and smoothed using an isotropic Gaussian kernel of 0.5 mm full width at half maximum. Ratio images were masked using a whole brain mask to remove the extra-cerebral signal prior to the statistical parametric mapping analysis, and the analysis was performed without global normalization due to the use of ratio images. Between-group effects were tested for each tracer using a voxel-wise two-sample t-test. An uncorrected voxel-level significance threshold (p < 0.01) was used, and subsequently a cluster-level family-wise error correction at p < 0.01 was applied.

**Data Analysis and Statistics**

The results are reported as average ± standard deviations (SDs). All statistical analyses were calculated using GraphPad Prism (GraphPad Software, v. 5.01, San Diego, CA, USA).

The differences in [18F]F-DPA, [18F]DPA-714, and [11C]PBR28 SUVRCB between TG and WT animals in the different time frames shown in Fig. 2 were calculated using the Mann–Whitney test.

The differences in peak/60-min ratios shown in Table 1 for [18F]F-DPA, [18F]DPA-714, and [11C]PBR28 and the differences between TG/WT ratios for [18F]F-DPA, [18F]DPA-714, and [11C]PBR28 for the different brain regions shown in Table 2 were analyzed using repeated-measures ANOVA with Tukey’s post hoc test for multiple comparison.

The residuals followed a normal distribution. Differences were considered significant for values of p < 0.05.

**Results**

In previous studies we have performed longitudinal PET studies using [18F]F-DPA and [18F]DPA-714 in the APP-PS1/21 mouse model, together with parallel immunohistochemical studies to assess amyloid deposition and glial activation [11, 25]. Based on the previous studies, we chose to use

| | [18F]F-DPA | [18F]DPA-714 | [11C]PBR28 |
|---|---|---|---|
| **Brain** | | | |
| Peak | 4.83 | 2.69 | 3.59 |
| 60 min | 1.37 | 1.79 | 1.89 |
| Peak/60 min | 3.52 | 1.50 *** | 1.90 *** |
| **Cortex** | | | |
| Peak | 4.26 | 2.35 | 3.13 |
| 60 min | 1.17 | 1.51 | 1.60 |
| Peak/60 min | 3.64 | 1.55 *** | 1.95 *** |
| **Hippocampus** | | | |
| Peak | 4.84 | 2.94 | 3.89 |
| 60 min | 1.13 | 1.68 | 1.72 |
| Peak/60 min | 4.27 | 1.75 *** | 2.26 *** |
| **Striatum** | | | |
| Peak | 4.72 | 2.57 | 3.64 |
| 60 min | 1.07 | 1.46 | 1.59 |
| Peak/60 min | 4.41 | 1.76 *** | 2.29 *** |
| **Thalamus** | | | |
| Peak | 5.29 | 3.02 | 4.10 |
| 60 min | 1.05 | 1.54 | 1.63 |
| Peak/60 min | 5.02 | 1.96 *** | 2.52 *** |

Averaged %ID/mL for [18F]F-DPA, [18F]DPA-714, and [11C]PBR28 (n = 5–6) at peak uptake and 60 min after injection, together with peak/60-min ratios for whole brain, cortex, hippocampus, striatum, and thalamus in wild-type (WT) mice. * denotes significant differences between [18F]F-DPA peak/60-min ratios and [18F]DPA-714 and [11C]PBR28 peak/60-min ratios. # denotes significant differences between [18F]DPA-714 peak/60-min ratios and [11C]PBR28 peak/60-min ratios. *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.05
ences between $^{18}$F-DPA-714 and $^{11}$C-PBR28 SUVRCB TG/WT ratios. * denotes significant differences between $^{18}$F-DPA SUVRCB TG/WT ratios, and $^{18}$F-DPA-714, and $^{11}$C-PBR28 SUVRCB TG/WT ratios. # denotes significant differences between $^{18}$F-DPA-714 and $^{11}$C-PBR28 SUVRCB TG/WT ratios. ** denotes significant differences between $^{18}$F-DPA-714 and and $^{11}$C-PBR28 SUVRCB TG/WT ratios. ## denotes significant differences between $^{18}$F-DPA-714 and $^{11}$C-PBR28 SUVRCB TG/WT ratios.

### 9-month-old mice in the current comparison due the extensive pathology in the AD model mice and clear PET signal.

**In vivo $^{18}$F-DPA, $^{18}$F-DPA-714, and $^{11}$C-PBR28 Uptake in WT Mice**

The graphs in Fig. 1 show the 60-min time-activity curves for whole brain, cortex, hippocampus, striatum, and thalamus of the APP/PS1-21 (WT) mice at different periods after injection (10–20, 20–40, and 40–60 min) using $^{18}$F-DPA, $^{18}$F-DPA-714, and $^{11}$C-PBR28. Table 1 shows detailed uptake information for all regions (Figs. 3a–e). In the case of $^{18}$F-DPA, the SUVRCB differences between WT and TG mice were highly significant ($p < 0.001$) in all the studied areas in the three studied periods (Figs. 3a–e). In the case of $^{18}$F-DPA, there were no significant differences in the 9–12 min-time period, but the differences were significant in the 20–40 min ($p < 0.01$) and 40–60 min ($p < 0.01$) periods for all regions (Figs. 3f–j). For $^{11}$C-PBR28 at 10–20 min, the SUVRCB differences between WT and TG were already significant for all the analyzed regions ($p < 0.05$), increasing in significance at 20–40 min ($p < 0.001$) and at 40–60 min ($p < 0.001$) (Figs. 3k–o).

**In vivo $^{18}$F-DPA, $^{18}$F-DPA-714, and $^{11}$C-PBR28 Uptake in APP/PS1-21 Mice**

Together with the WT mice, 6 aged-matched APP-PS1/21 TG mice were scanned with $^{18}$F-DPA, $^{18}$F-DPA-714, and $^{11}$C-PBR28. Figure 2 shows representative images for $^{18}$F-DPA, $^{18}$F-DPA-714, and $^{11}$C-PBR28 in TG and WT mice. To compare $^{18}$F-DPA, $^{18}$F-DPA-714, and $^{11}$C-PBR28 in a mouse model of moderate neuroinflammation, we used 9-month-old APP/PS1-21 AD model mice. SUVRCB values were calculated for the whole brain, cortex, hippocampus, striatum, and thalamus of the APP/PS1-21 (WT) and wild-type (WT) mice at different periods after $^{18}$F-DPA, $^{18}$F-DPA-714, and $^{11}$C-PBR28 injection.

Table 2 summarizes the averaged SUVRCB values for TG and WT mice and the ratios of SUVRCB values for TG and WT in the different time periods (10–20, 20–40, and 40–60 min) and regions for all three radiotracers. At the 10–20 min period, the $^{18}$F-DPA TG/WT ratios for all the studied brain regions were significantly higher ($p < 0.001$) than those of $^{18}$F-DPA-714 and $^{11}$C-PBR28. In addition, during that period, the TG/WT ratios of $^{18}$F-DPA-714 and $^{11}$C-PBR28 in the hippocampus and THA were also significantly different ($p < 0.05$).
Fig. 1 Time-activity curves as percentage of injected dose/mL (%ID/mL) for $[^{18}F]$F-DPA, $[^{18}F]$DPA-714, and $[^{11}C]$PBR28 in whole brain (a), cortex (b), hippocampus (c), striatum (d), thalamus (e), and cerebellum (f) in the same wild-type (WT) mice ($n=6$). Values are expressed as the average ± SD.

Fig. 2 Representative 40–60-min summed images for $[^{18}F]$F-DPA (left column), $[^{18}F]$DPA-714 (middle column), and $[^{11}C]$PBR28 (right column) in transgenic APP/PS1/21 (TG) (top row) and wild-type (WT) (bottom row) mice.
Fig. 3 Standardized uptake value ratios to cerebellum (SUVR<sub>cbl</sub>) differences between wild-type (WT) and transgenic APP/PS1/21 (TG) mice at different periods after injection (10–20, 20–40, and 40–60 min) in whole brain, cortex, hippocampus, striatum, and thalamus are shown for [18F]DPA (a–e), [18F]DPA-714 (f–j), and [11C]PBR28 (k–o). Values are expressed as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. The same WT (n = 6) and TG mice (n = 5–6) were imaged with all tracers.
STR, and THA and between the TG/WT ratios of $[^{18}F]$F-DPA and $[^{11}C]$PBR28 in HIPPO, STR, and THA.

In the 40–60-min period, the differences between the TG/WT ratios of $[^{18}F]$F-DPA and $[^{18}F]$DPA-714 in HIPPO ($p<0.001$), STR, and THA ($p<0.01$) remained highly significant; however only low significance was seen between the TG/WT ratios of $[^{18}F]$F-DPA and $[^{11}C]$PBR28 in the HIPPO ($p<0.05$). Significant differences were also detected for the HIPPO in all three time periods when comparing the TG/WT ratios of $[^{18}F]$DPA-714 and $[^{11}C]$PBR28.

We performed a voxel-wise analysis of the PET images to study the differences in tracer uptake between WT and TG mice at 10–20, 20–40, and 40–60 min after injection at the voxel level. Figure 4 shows coronal and axial images of $[^{18}F]$F-DPA, $[^{18}F]$DPA-714, and $[^{11}C]$PBR28 at the different time points and the cluster sizes. Due to the extensive signal, and after filtering, only a single cluster was detected. In the 10–20 min time frame, the cluster size for $[^{18}F]$F-DPA was 292 mm$^3$, while for $[^{18}F]$DPA-714 and $[^{11}C]$PBR28, the sizes were 83 mm$^3$ and 156 mm$^3$, respectively. In the next time frames, the $[^{18}F]$DPA-714 and $[^{11}C]$PBR28 cluster sizes increased significantly until the 40–60 min time frame. At this last time frame, the cluster sizes were 277 mm$^3$ ($[^{18}F]$F-DPA), 240 mm$^3$ ($[^{18}F]$DPA-714), and 251 mm$^3$ ($[^{11}C]$PBR28). Cortical and hippocampal uptake areas of higher significance are indicated by the higher t-scores. The voxel-based analysis also showed no differences in uptake between WT and TG in the CB.

**Discussion**

Several studies have been performed in different animal models of AD using first-generation TSPO radiotracers such as $[^{18}F]$FE-DAA1106 [26, 27], $[^{11}C]$AC-5216 [27], and $[^{11}C]$PK-11195 [4, 28], with marked disparities in the results. More recent studies using novel TSPO tracers such as $[^{11}C]$PBR28 [29], $[^{18}F]$GE-180 [30, 31], and $[^{18}F]$DPA-714 [15, 16] have shown more consistent results in detecting inflammation.

In humans, increased microglial activation has been shown in post mortem brain samples of AD patients, although the role of this activation is still controversial [32, 33]. The first human PET studies targeting neuroinflammation were performed using $[^{11}C]$PK11195, with contradictory results [34–37]. The varied findings with $[^{11}C]$PK11195 could be explained by the variability in the studied populations, as well as the limitations of the radiotracer itself, including high non-specific binding, high lipophilicity, low blood–brain barrier penetration, and low binding potential [6, 7, 38]. Studies using newer TSPO radiotracers have also shown heterogeneous results in different populations [19, 39–41]. Among these novel tracers, $[^{18}F]$DPA-714 has a better signal-to-noise ratio and a greater affinity than $[^{11}C]$PK11195 [13]. The first human studies with $[^{18}F]$DPA-714 concluded that this tracer cannot be used to distinguish individual AD patients from healthy subjects [19]. In contrast, a more recent human prospective study looked into early and protective microglial activation in AD and concluded that $[^{18}F]$DPA-714 can be a good tool for assessing neuroinflammation in early and pre-clinical AD [20].

In the current study, we have shown in WT mice that $[^{18}F]$F-DPA has better brain penetration and faster washout than $[^{18}F]$DPA-714 and $[^{11}C]$PBR28, as shown in Table 1 by the peak tracer uptake and the highly significant differences in peak uptake/60-min ratios. In addition, we compared
the uptake in the brains of 9-month-old APP/PS1-21 mice. We have shown in two longitudinal studies that significant \([^{18}\text{F}]\text{F}-\text{DPA}\) and \([^{18}\text{F}]\text{DPA-714}\) uptake can be measured in 9-month-old APP/PS1-21 model mice \([11, 16]\) and therefore chose animals of that age for the direct tracer comparison. In the current study, higher SUV\text{RC}_{B} values were achieved with \([^{18}\text{F}]\text{F}-\text{DPA}\) compared with \([^{18}\text{F}]\text{DPA-714}\) or \([^{11}\text{C}]\text{PBR28}\), with significant differences between TG and WT mice in \([^{18}\text{F}]\text{F}-\text{DPA}\) uptake as soon as 20 min after the injection. In addition, the voxel-wise analysis confirmed the differences between the tracers, showing that the high uptake and fast washout of \([^{18}\text{F}]\text{F}-\text{DPA}\) allows the detection of differences in uptake between the WT and TG mice at earlier time frames compared with \([^{18}\text{F}]\text{F}-\text{DPA-714}\) and \([^{11}\text{C}]\text{PBR28}\).

In the current study, we used the CB as the reference region for analyses of the PET images. The use of the CB as a reference region is well established for amyloid quantification with \([^{11}\text{C}]\text{PIB}\), but the choice of the CB is more controversial for analyzing the binding of TSPO tracers. We previously observed an age-dependent increase in tracer accumulation in the cerebellum; however, this increase resulted in a significant difference between TG and WT animals only from the age of 12 months onwards, with no significant difference observed at 9 months. The reference region (hypothalamus) employed in the previous study \([10]\) is unsuitable as an in vivo reference region due to its proximity to the pituitary gland. Our use of the CB as the reference region for \([^{18}\text{F}]\text{F}-\text{DPA}\), \([^{18}\text{F}]\text{DPA-714}\), and \([^{11}\text{C}]\text{PBR28}\) was based on our PET imaging data showing no differences in tracer uptake between TG and WT mice, as shown by the voxel-wise analysis in Fig. 4, and the cerebellar time-activity curves in Suppl. Figure 1. In addition, in previous studies, the CB has proven to be a reliable reference region, and its use as such also decreases group variability \([11, 16, 46]\). From our study we can conclude that the novel TSPO radiotracer \([^{18}\text{F}]\text{F}-\text{DPA}\) shows higher initial brain uptake, faster clearance, and better target-to-background ratios than \([^{18}\text{F}]\text{F}-\text{DPA-714}\) and \([^{11}\text{C}]\text{PBR28}\) when the comparisons are made with the same AD and WT animals. Furthermore, due to the washout kinetics, higher SUV\text{RC}_{B} values are measured with \([^{18}\text{F}]\text{F}-\text{DPA}\) and at earlier time points after injection. With all of these characteristics, the novel tracer \([^{18}\text{F}]\text{F}-\text{DPA}\) could prove very useful for the detection of low levels of microglial activation inflammation and, because of its fast clearance, would permit shorter dynamic scans.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s11307-021-01646-5.

**Acknowledgements** We thank Markus Matilainen for his support with the statistical analyses, Marko Vehmanen and Elisa Riuttala for laboratory technical support, the Central Animal Laboratory (CAL) for laboratory animal maintenance, and the staff of the accelerator laboratory.

**Authors’ Contributions** FRL-P planned the study, participated in the PET imaging work, and was the main contributor to the image analysis, statistical analysis, and manuscript writing. TK and AK performed the synthesis of \([^{18}\text{F}]\text{F}-\text{DPA}\) and \([^{18}\text{F}]\text{DPA-714}\). AD and FD synthesized \([^{11}\text{C}]\text{PBR28}\). SH performed the \([^{11}\text{C}]\text{PBR28}\) synthesis. AD and FD synthesized \([^{18}\text{F}]\text{F}-\text{DPA}\) and \([^{18}\text{F}]\text{DPA-714}\) precursors. JOR contributed to the planning and funding of the study. MH-S contributed to study planning and manuscript writing. OS contributed to the radiochemistry work, study planning, the funding of the study, and manuscript writing.

**Funding** Open access funding provided by University of Turku (UTU) including Turku University Central Hospital. This study was supported by the EC 7th Framework Programs FP7-PEOPLE-2012-ITN-RADIOMI-316882 and HEALTH-F2-2011-278850 (INMIND), by the state funding for university level health research (ERVA, grant no 13250), and by the Academy of Finland (grant nos. 310962 and 334310).

**Data Availability** All data were handled in accordance with the comprehensive quality system in effect at the Turku PET Centre and following the open science and research data policy in use by the University of Turku (https://www.utu.fi/sites/default/files/public%3A/media/file/data-policy.pdf). The raw data from the PET animal imaging studies and laboratory analyses are archived in the Turku PET Centre archiving systems. These data will be available upon agreement with the Turku PET Centre.
Declarations
Conflict of Interests The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Guilarte TR, Kuhlmann AC, O Callaghan JP, Miceli RC (1995) Enhanced expression of peripheral benzodiazepine receptors in trimethyl‑alanine‑exposed rat brain: a biomarker of neurotoxicity. Neurotoxicology 16(3):441–450
2. Hashimoto K, Inoue O, Suzuki K, Yamasaki T, Kojima M (1989) Synthesis and evaluation of C13‑PK 11195 for in vivo study of peripheral‑type benzodiazepine receptors using positron emission tomography. Ann Nucl Med 3(2):63–71
3. James ML, Fulton RR, Vercouillie J, Henderson DJ, Garreau L, Chalon S et al (2008) DPA‑714, a new translocator protein‑specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med 49(5):814–822. https://doi.org/10.2967/jnumed.107.046151
4. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18 kDa) in microglia: from pathology to imaging (2006) Prog Neurobiol 80(6):308–22. doi: https://doi.org/10.1016/j.pneurobio.2006.10.002
5. Perani D, Iaccarino L, Lammertsma AA, Windhorst AD, Edison P, Boellaard R et al (2019) A new perspective for advanced positron emission tomography‑based molecular imaging in neurodegenerative proteinopathies. Alzheimer’s Dementia 15(8):1081–1103. https://doi.org/10.1016/j.jalz.2019.02.004
6. Belloli S, Moresco RM, Matarrrese M, Biella G, Sanvito F, Simonelli P et al (2004) Evaluation of three quinoline‑carboxamide derivatives as potential radiogand for the in vivo PET imaging of neurodegeneration. Neurochem Int 44(6):433–440
7. Lockhart A, Davis B, Matthews JC, Rahmoune H, Hong G, Gec A et al (2003) The peripheral benzodiazepine receptor ligand PK11195 binds with high affinity to the acute phase reactant alpha1‑acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. Nucl Med Biol 30(2):199–206
8. Briard E, Zogghi SS, Siméon FG, Imaizumi M, Gourley JP, Shetty HP et al (2009) Single‑step high‑yield radiosynthesis and evaluation of a sensitive 18F‑labeled ligand for imaging brain peripheral benzodiazepine receptors with PET. J Med Chem 52(3):688–699. https://doi.org/10.1021/jm8011855
9. Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore J et al (2012) [18F]FGE‑180: a novel fluorine‑18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO). Bioorg Med Chem Lett 22(3):1308‑1313. https://doi.org/10.1016/j.bmcl.2011.12.084
10. Keller T, López‑Picón FR, Krzyczmonik A, Forsback S, Rajander J et al (2020) Comparison of high and low molar activity TSPO tracer [18F]F‑DPA in model of Alzheimer’s disease. J Cereb Blood Flow Metab 40(5):1012–1020. https://doi.org/10.1177/027167881816677900
11. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L et al (2006) In vivo positron emission tomographic imaging of glial responses to amyloid‑beta and tau pathologies in mouse models of Alzheimer’s disease and related disorders. J Neurosci 31(12):4720–4730. https://doi.org/10.1523/JNEUROSCI.2312‑08.2008
12. Bi J, Maeda J, Sawada M, Ono M, Okaitchi T, Inaji M et al (2008) Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer’s and other CNS pathologies. J Neurosci 28(47):12255–12267. https://doi.org/10.1523/JNEUROSCI.2312‑08.2008
13. Maeda J, Zhang MR, Okaitchi T, Bi J, Ono M, Hattori S et al (2011) In vivo positron emission tomographic imaging of glial responses to amyloid‑beta and tau pathologies in mouse models of Alzheimer’s disease and related disorders. J Neurosci 31(12):4720–4730. https://doi.org/10.1523/JNEUROSCI.3076‑10.2011
14. Rapic S, Backes H, Viel T, Kummer MP, Monfared P, Neumaier B et al (2013) Imaging microglial activation and glucose consumption in a...
29. Mirzaei N, Tang SP, Ashworth S, Coello C, Plisson C, Pascshier J et al (2008) In vivo imaging of microglial activation by positron emission tomography with $^{11}$C]PBR28 in the 5XFAD model of Alzheimer’s disease. Glia 64(6):993–1006. https://doi.org/10.1002/glia.22978

30. Liu B, Le KK, Park MA, Wang S, Belanger AP, Dubey S et al (2015) In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by $^{18}$F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer’s Transgenic Mice. J Neurosci 35(47):15716–15730. https://doi.org/10.1523/JNEUROSCI.09996-15.2015

31. Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T et al (2017) Increase of TREM2 during Aging of an Alzheimer’s Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. Front Aging Neurosci 9:8. https://doi.org/10.3389/fnagi.2017.00008

32. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosser F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14(4):388–405. https://doi.org/10.1016/S1474-4422(15)70016-5

33. Prokop S, Miller KR, Heppner FL (2013) Microglia actions in Alzheimer’s disease. Acta Neuropathol 126(4):461–477

34. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE et al (2001) In-vivo measurement of activated microglia in dementia. Lancet 358(9280):461–467. https://doi.org/10.1016/S0140-6736(01)05625-2

35. Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST et al (2009) Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 66(1):60–67. https://doi.org/10.1001/archneur.2008.511

36. Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF et al (2013) Microglial activation in Alzheimer’s disease: an (R)-$^{11}$C]PK11195 positron emission tomography study. Neurobiol Aging 34(1):128–136. https://doi.org/10.1016/j.neurobiolaging.2012.04.021

37. Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K et al (2015) Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement 11(6):608–21.e7. https://doi.org/10.1016/j.jalz.2014.06.016

38. Cumming P, Burgher B, Patkar O, Breakfastp M, Vasdev N, Thomas P et al (2018) Sifting through the surfeit of neuroinflammation tracers. J Cereb Blood Flow Metab 38(2):204–224. https://doi.org/10.1177/0271678X17748786

39. Feeney C, Scott G, Raffel J, Roberts S, Coello C, Jolly A et al (2016) Kinetic analysis of the translocator protein positron emission tomography ligand $^{18}$F-GE-180 in the human brain. Eur J Nucl Med Mol Imaging 43(12):2201–2210. https://doi.org/10.1007/s00259-016-3444-z

40. Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y et al (2012) Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with $^{11}$C]DAA1106. Psychiatry Res 203(1):67–74. https://doi.org/10.1016/j.psychres.2011.08.013

41. Lyoo CH, Ikawa M, Liow JS, Zoghibi SS, Morse CL, Pike VW et al (2015) Cerebellum Can Serve As A Pseudo-Reference Region in Alzheimer’s Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. J Nucl Med 56(5):701–706. https://doi.org/10.2967/jnumed.114.146027

42. Kim GR, Paeng JC, Jung JH, Moon BS, Lopalco A, Denora N, et al (2018) Assessment of TSPO in a rat experimental autoimmune myocardiitis model: a comparison study between $^{18}$FFluoromethyl-PBR28 and $^{18}$F]CB251. Int J Mol Sci 19(1). https://doi.org/10.3390/ijms19010276

43. Chaney A, Cropper HC, Johnson EM, Lechtenberg KJ, Peterson TC, Stevens MY et al (2019) $^{18}$C-DPA-714 Versus $^{18}$F-GE-180: A preclinical comparison of translocator protein 18 kDa PET tracers to visualize acute and chronic neuroinflammation in a mouse model of ischemic stroke. J Nucl Med 60(1):122–128. https://doi.org/10.2967/jnumed.118.209155

44. Boutin H, Prenant C, Marory R, Galea J, Greenhalgh AD, Smigova A et al (2013) $^{18}$F-GE-180: a novel TSPO radiotracer compared to $^{11}$C-R-PK11195 in a preclinical model of stroke. Eur J Nucl Med Mol Imaging 42(3):503–511. https://doi.org/10.1007/s00259-014-2939-8

45. Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF et al (2013) Microglial activation in Alzheimer’s disease: an (R)-$^{11}$C]PK11195 positron emission tomographic imaging in Alzheimer disease. Acta Neuropathol 126(4):461–477.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.